Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.

Wahid R, Pasetti MF, Maciel M Jr, Simon JK, Tacket CO, Levine MM, Sztein MB.

Clin Immunol. 2011 Feb;138(2):187-200. doi: 10.1016/j.clim.2010.11.006. Epub 2010 Dec 10.

2.

Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues.

El-Kamary SS, Pasetti MF, Mendelman PM, Frey SE, Bernstein DI, Treanor JJ, Ferreira J, Chen WH, Sublett R, Richardson C, Bargatze RF, Sztein MB, Tacket CO.

J Infect Dis. 2010 Dec 1;202(11):1649-58. doi: 10.1086/657087. Epub 2010 Oct 27. Erratum in: J Infect Dis. 2011 Apr 1;203(7):1036.

3.

Relatedness of Vibrio cholerae O1/O139 isolates from patients and their household contacts, determined by multilocus variable-number tandem-repeat analysis.

Kendall EA, Chowdhury F, Begum Y, Khan AI, Li S, Thierer JH, Bailey J, Kreisel K, Tacket CO, LaRocque RC, Harris JB, Ryan ET, Qadri F, Calderwood SB, Stine OC.

J Bacteriol. 2010 Sep;192(17):4367-76. doi: 10.1128/JB.00698-10. Epub 2010 Jun 28.

4.

Vaginal microbiome of reproductive-age women.

Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, Karlebach S, Gorle R, Russell J, Tacket CO, Brotman RM, Davis CC, Ault K, Peralta L, Forney LJ.

Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4680-7. doi: 10.1073/pnas.1002611107. Epub 2010 Jun 3.

5.

Plant-based oral vaccines: results of human trials.

Tacket CO.

Curr Top Microbiol Immunol. 2009;332:103-17. doi: 10.1007/978-3-540-70868-1_6. Review.

PMID:
19401823
6.

Generation of specific effector and memory T cells with gut- and secondary lymphoid tissue- homing potential by oral attenuated CVD 909 typhoid vaccine in humans.

Wahid R, Salerno-Gonçalves R, Tacket CO, Levine MM, Sztein MB.

Mucosal Immunol. 2008 Sep;1(5):389-98. doi: 10.1038/mi.2008.30. Epub 2008 Jul 2.

7.

Plant-based vaccines against diarrheal diseases.

Tacket CO.

Trans Am Clin Climatol Assoc. 2007;118:79-87.

8.

An in vivo expression technology screen for Vibrio cholerae genes expressed in human volunteers.

Lombardo MJ, Michalski J, Martinez-Wilson H, Morin C, Hilton T, Osorio CG, Nataro JP, Tacket CO, Camilli A, Kaper JB.

Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18229-34. Epub 2007 Nov 6.

9.

CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression.

Tacket CO, Levine MM.

Clin Infect Dis. 2007 Jul 15;45 Suppl 1:S20-3. Review.

PMID:
17582563
10.

Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909.

Wahid R, Salerno-Gonçalves R, Tacket CO, Levine MM, Sztein MB.

Vaccine. 2007 Feb 9;25(8):1416-25. Epub 2006 Nov 3.

11.

Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers.

Dowling TC, Chavaillaz PA, Young DG, Melton-Celsa A, O'Brien A, Thuning-Roberson C, Edelman R, Tacket CO.

Antimicrob Agents Chemother. 2005 May;49(5):1808-12.

12.

Plant-derived vaccines against diarrheal diseases.

Tacket CO.

Vaccine. 2005 Mar 7;23(15):1866-9. Review.

PMID:
15734057
13.

Garden-variety vaccines: antigens derived from transgenic plants.

Tacket CO.

Expert Rev Vaccines. 2004 Oct;3(5):529-31. Review.

PMID:
15485332
14.

Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn.

Tacket CO, Pasetti MF, Edelman R, Howard JA, Streatfield S.

Vaccine. 2004 Oct 22;22(31-32):4385-9.

PMID:
15474732
15.

Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.

Tacket CO, Pasetti MF, Sztein MB, Livio S, Levine MM.

J Infect Dis. 2004 Aug 1;190(3):565-70. Epub 2004 Jun 30.

PMID:
15243933
16.

Plant-derived vaccines against diarrhoeal diseases.

Tacket CO.

Expert Opin Biol Ther. 2004 May;4(5):719-28. Review.

PMID:
15155163
17.

Dose-dependent neutralizing-antibody responses to vaccinia.

Belshe RB, Newman FK, Frey SE, Couch RB, Treanor JJ, Tacket CO, Yan L.

J Infect Dis. 2004 Feb 1;189(3):493-7. Epub 2004 Jan 23.

PMID:
14745707
18.

Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines.

Kanesa-Thasan N, Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Coster TS, Kim-Ahn GJ, Dubois DR, Putnak JR, King A, Summers PL, Innis BL, Eckels KH, Hoke CH Jr.

Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):17-23. Erratum in: Am J Trop Med Hyg. 2004 Mar;70(3):336.

PMID:
14740951
19.

Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers.

Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK.

Clin Immunol. 2003 Sep;108(3):241-7.

PMID:
14499247
20.

High-risk research in healthy volunteers.

Tacket CO.

J Investig Med. 2003 Feb;51 Suppl 1:S1. No abstract available.

PMID:
12664946
21.

Concomitant induction of CD4+ and CD8+ T cell responses in volunteers immunized with Salmonella enterica serovar typhi strain CVD 908-htrA.

Salerno-Gonçalves R, Wyant TL, Pasetti MF, Fernandez-Viña M, Tacket CO, Levine MM, Sztein MB.

J Immunol. 2003 Mar 1;170(5):2734-41.

22.

Clinical responses to undiluted and diluted smallpox vaccine.

Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, Newman FK, Atmar RL, Edelman R, Nolan CM, Belshe RB; National Institute of Allergy and Infectious Diseases Smallpox Vaccine Study Group.

N Engl J Med. 2002 Apr 25;346(17):1265-74. Epub 2002 Mar 28.

23.

Host-Salmonella interaction: human trials.

Levine MM, Tacket CO, Sztein MB.

Microbes Infect. 2001 Nov-Dec;3(14-15):1271-9. Review.

PMID:
11755415
24.

Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA.

Am J Trop Med Hyg. 2000 Jun;62(6):681-5.

PMID:
11304054
25.

Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C.

Tacket CO, Galen J, Sztein MB, Losonsky G, Wyant TL, Nataro J, Wasserman SS, Edelman R, Chatfield S, Dougan G, Levine MM.

Clin Immunol. 2000 Nov;97(2):146-53.

PMID:
11027455
26.

Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes.

Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ.

J Infect Dis. 2000 Jul;182(1):302-5. Epub 2000 Jul 6.

PMID:
10882612
27.

Role of EspB in experimental human enteropathogenic Escherichia coli infection.

Tacket CO, Sztein MB, Losonsky G, Abe A, Finlay BB, McNamara BP, Fantry GT, James SP, Nataro JP, Levine MM, Donnenberg MS.

Infect Immun. 2000 Jun;68(6):3689-95.

28.

A review of oral vaccination with transgenic vegetables.

Tacket CO, Mason HS.

Microbes Infect. 1999 Aug;1(10):777-83. Review.

PMID:
10816083
29.

Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers.

Tacket CO, Sztein MB, Wasserman SS, Losonsky G, Kotloff KL, Wyant TL, Nataro JP, Edelman R, Perry J, Bedford P, Brown D, Chatfield S, Dougan G, Levine MM.

Infect Immun. 2000 Mar;68(3):1196-201.

30.
31.
32.

Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device.

Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, Edelman R.

Vaccine. 1999 Jul 16;17(22):2826-9.

PMID:
10438052
33.

Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama.

Taylor DN, Sanchez JL, Castro JM, Lebron C, Parrado CM, Johnson DE, Tacket CO, Losonsky GA, Wasserman SS, Levine MM, Cryz SJ.

Infect Immun. 1999 Apr;67(4):2030-4.

34.

Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative.

Bartlett JA, Wasserman SS, Hicks CB, Dodge RT, Weinhold KJ, Tacket CO, Ketter N, Wittek AE, Palker TJ, Haynes BF.

AIDS. 1998 Jul 30;12(11):1291-300.

PMID:
9708408
35.

Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato.

Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ.

Nat Med. 1998 May;4(5):607-9.

PMID:
9585236
36.

Validation of a volunteer model of cholera with frozen bacteria as the challenge.

Sack DA, Tacket CO, Cohen MB, Sack RB, Losonsky GA, Shimko J, Nataro JP, Edelman R, Levine MM, Giannella RA, Schiff G, Lang D.

Infect Immun. 1998 May;66(5):1968-72.

37.

Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli.

Freedman DJ, Tacket CO, Delehanty A, Maneval DR, Nataro J, Crabb JH.

J Infect Dis. 1998 Mar;177(3):662-7.

PMID:
9498445
38.

Investigation of the roles of toxin-coregulated pili and mannose-sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae O139 infection.

Tacket CO, Taylor RK, Losonsky G, Lim Y, Nataro JP, Kaper JB, Levine MM.

Infect Immun. 1998 Feb;66(2):692-5.

39.

Effect of prior experimental human enteropathogenic Escherichia coli infection on illness following homologous and heterologous rechallenge.

Donnenberg MS, Tacket CO, Losonsky G, Frankel G, Nataro JP, Dougan G, Levine MM.

Infect Immun. 1998 Jan;66(1):52-8.

40.

Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.

Taylor DN, Tacket CO, Losonsky G, Castro O, Gutierrez J, Meza R, Nataro JP, Kaper JB, Wasserman SS, Edelman R, Levine MM, Cryz SJ.

Infect Immun. 1997 Sep;65(9):3852-6.

41.

Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system.

Tacket CO, Kelly SM, Schödel F, Losonsky G, Nataro JP, Edelman R, Levine MM, Curtiss R 3rd.

Infect Immun. 1997 Aug;65(8):3381-5. Erratum in: Infect Immun 1997 Sep;65(9):3981.

42.

Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 111.

Tacket CO, Kotloff KL, Losonsky G, Nataro JP, Michalski J, Kaper JB, Edelman R, Levine MM.

Am J Trop Med Hyg. 1997 May;56(5):533-7.

PMID:
9180604
43.

Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity.

Losonsky GA, Lim Y, Motamedi P, Comstock LE, Johnson JA, Morris JG Jr, Tacket CO, Kaper JB, Levine MM.

Clin Diagn Lab Immunol. 1997 May;4(3):264-9.

44.

Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans.

Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Nataro JP, Edelman R, Pickard D, Dougan G, Chatfield SN, Levine MM.

Infect Immun. 1997 Feb;65(2):452-6.

45.

Vibrio cholerae O1 can assume a chlorine-resistant rugose survival form that is virulent for humans.

Morris JG Jr, Sztein MB, Rice EW, Nataro JP, Losonsky GA, Panigrahi P, Tacket CO, Johnson JA.

J Infect Dis. 1996 Dec;174(6):1364-8.

PMID:
8940236
46.

New evidence for an inflammatory component in diarrhea caused by selected new, live attenuated cholera vaccines and by El Tor and Q139 Vibrio cholerae.

Silva TM, Schleupner MA, Tacket CO, Steiner TS, Kaper JB, Edelman R, Guerrant R.

Infect Immun. 1996 Jun;64(6):2362-4.

47.

Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge.

Tacket CO, Losonsky G, Nataro JP, Comstock L, Michalski J, Edelman R, Kaper JB, Levine MM.

J Infect Dis. 1995 Sep;172(3):883-6.

PMID:
7658089
48.

Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers.

Morris JG Jr, Losonsky GE, Johnson JA, Tacket CO, Nataro JP, Panigrahi P, Levin MM.

J Infect Dis. 1995 Apr;171(4):903-8.

PMID:
7706818
49.

Heterogeneity of enteroaggregative Escherichia coli virulence demonstrated in volunteers.

Nataro JP, Deng Y, Cookson S, Cravioto A, Savarino SJ, Guers LD, Levine MM, Tacket CO.

J Infect Dis. 1995 Feb;171(2):465-8.

PMID:
7844392
50.

Extension of the volunteer challenge model to study South American cholera in a population of volunteers predominantly with blood group antigen O.

Tacket CO, Losonsky G, Nataro JP, Wasserman SS, Cryz SJ, Edelman R, Levine MM.

Trans R Soc Trop Med Hyg. 1995 Jan-Feb;89(1):75-7.

PMID:
7747315

Supplemental Content

Loading ...
Support Center